Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Summit Therapeutics PLC
SMMTCurrent price
20.69 USD
+0.78 USD (+3.92%)
Last closed
19.75 USD
Company
www.summittxinc.com
ISIN
US86627T1088
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
13 775 528 960 USD
Yield for 12 month
+530.79 %
1Y
3Y
5Y
10Y
15Y
SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. Address: 601 Brickell Key Drive, Miami, FL, United States, 33131
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
33.01 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+704 295 USD
Current Quarter
–
Last Quarter
–
Current Year
-2 050 000 USD
Last Year
-1 809 705 USD
Current Quarter
-19 999 USD
Last Quarter
-20 000 USD
Key Figures SMMT
1 year
3 years
5 years
10 years
EBITDA
-181 490 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-31.47 %
PEG Ratio
–
Return On Equity TTM
-73.21 %
Wall Street Target Price
33.01 USD
Revenue TTM
–
Book Value
0.59 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
705 000 USD
Earnings per share
-0.23 USD
Diluted Eps TTM
-0.23 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SMMT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History SMMT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:1
Payout Ratio
–
Last Split Date
21.09.2020
Stock Valuation SMMT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
6 425.28
Price Sales TTM
753.90
Enterprise Value EBITDA
-5.32
Price Book MRQ
31.46
Financials SMMT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SMMT
For 52 weeks
2.10 USD
33.89 USD
50 Day MA
19.62 USD
Shares Short Prior Month
15 987 477
200 Day MA
11.79 USD
Short Ratio
8.65
Shares Short
16 840 640
Short Percent
14.17 %
BeatStart